secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-07-13T11:11:25+00:00
Accession:  0001104659-26-082850
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata receives FDA agreement on pediatric study plan for AP-SA02 in S. aureus bacteremia
--------------------------------------------------------------------------------

- FDA agreed on Initial Pediatric Study Plan (iPSP) for AP-SA02 as adjunct treatment for complicated S. aureus bacteremia in patients up to 17 years.
- iPSP agreement is a regulatory requirement that must be met before submitting a Biologics License Application (BLA).
- Pediatric studies will be deferred until adult Phase 3 safety/efficacy data are available; adult Phase 3 expected to start H2 2026.
- CEO Dr. Deborah Birx highlighted the milestone as addressing vulnerable pediatric populations with limited treatment options.
- AP-SA02 has QIDP and Fast Track designations; Phase 2a results presented at IDWeek 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/0001104659-26-082850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926082850/tm2620286d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer